Physician profile

Michael Q Luu

Cardiovascular Disease · Pasadena, CA

NPI 1578520763

$6,238.64

in general payments reported to CMS, 2019-2025

32 companies · $648 in 2025

The $648 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,872.63

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $1,370.85 2019-2025
Pfizer INC. $802.47 2019-2025
Amgen INC. $796.75 2019-2025 Repatha
Actelion Pharmaceuticals US, INC. $703.93 2019-2025 Uptravi, Opsumit
Boston Scientific Corporation $565.81 2020-2023 Emblem Mri S-Icd
Abbott Laboratories $249.40 2021-2025 Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $190.67 2019-2025 Lifevest
E.R. Squibb & Sons, L.L.C. $161.02 2019-2024 Camzyos
Medtronic Vascular, INC. $144.49 2020
Ortho Dermatologics, A Division of Bausch Health US, LLC $142.50 2023 Duobrii, Siliq
Janssen Pharmaceuticals, INC $140.83 2019-2022
Kestra Medical Technology Services, INC. $130.87 2022-2025 Assure Wcd
Amarin Pharma, INC. $112.88 2019
Novo Nordisk INC $107.15 2022-2025 Ozempic, Rybelsus, Wegovy
Merck Sharp & Dohme LLC $83.32 2021-2025 Verquvo
Show all 32 companies
CompanyGeneral paymentsYearsTop products
Sanofi-Aventis U.S. LLC $81.81 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $75.28 2019
Cleerly, INC. $63.63 2025 Cleerly Labs, Cleerly Ischemia
Gilead Sciences, INC. $39.76 2019
Kiniksa Pharmaceuticals, LTD. $35.87 2022
Esperion Therapeutics, INC. $29.75 2024 Nexletol
Edwards Lifesciences Corporation $28.38 2019
Sobi, INC $24.02 2022
Alnylam Pharmaceuticals INC. $21.53 2019
Irhythm Technologies, INC. $20.91 2023 Zio Xt Patch
Astrazeneca Pharmaceuticals LP $18.54 2019
Mannkind Corporation $17.97 2023 Afrezza
Akcea Therapeutics, INC. $16.40 2019
Kowa Pharmaceuticals America, INC. $16.23 2019
Pulmonx Corporation $15.80 2023 Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve
Atricure, INC. $15.66 2021
Tactile Systems Technology INC $14.16 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Q Luu

$6,238.64

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $648 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/778406/michael-q-luu

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.